Decreasing Rates of Pediatric Bipolar Within an Outpatient Practice

Daniel Wesemann1

  • 1Daniel Wesemann, DNP, PMHNP-BC, APRN, is Project Leader, 2917, 28th Ave. A Moline, Illinois.

Insights

Pediatric bipolar disorder (PBD) diagnosis rates decreased in Iowa despite national increases. This study found provider diagnoses of PBD did not align with screening tool results, highlighting a need for better diagnostic criteria.

Area of Science:

  • Child and Adolescent Psychiatry
  • Mental Health Diagnostics
  • Behavioral Science

Background:

  • Pediatric bipolar disorder (PBD) prevalence is estimated at 1-3%, with national rates increasing over 400%.
  • Contrasting national trends, a decrease in PBD diagnoses was observed in Iowa (33%) and a specific clinic (51.2%) between 2008-2013.
  • This discrepancy prompted an examination of diagnostic practices for PBD in an outpatient mental health setting.

Purpose of the Study:

  • To investigate the diagnostic practices of pediatric bipolar disorder (PBD) by local providers.
  • To compare provider clinical diagnoses with results from standardized screening tools for PBD and ADHD.
  • To assess the agreement between screening measures and clinical judgment in diagnosing PBD.

Main Methods:

  • Parents completed screening packets including the Child Mania Rating Scale (CMRS), Child Behavior Checklist-Mania Scale (CBCL-MS), and NICHQ Vanderbilt to differentiate PBD from ADHD.
  • Symptom agreement analysis was conducted between the screening tools and the provider's clinical diagnoses.
  • Statistical analysis, including ANOVA and Tukey HSD posthoc tests, was used to compare screening results and clinical diagnoses.

Main Results:

  • Screening tools indicated PBD symptoms in 19.6% (CMRS) and 55.9% (CBCL-MS) of participants; 36.60% screened positive for ADHD (Vanderbilt).
  • No significant diagnostic agreement was found between screening data and provider clinical diagnoses for PBD (p < .05).
  • Providers' PBD diagnosis rates did not correlate with the prevalence of PBD symptoms identified by the screening instruments.

Conclusions:

  • Current screening measures for PBD show low agreement with clinical diagnoses in this outpatient setting.
  • Further research is required to refine diagnostic criteria and validate screening tools for distinguishing PBD from related disorders like ADHD.
  • Evidence is needed to guide clinical practice in accurately diagnosing PBD in children and adolescents.
Abstract

Related Concept Videos

Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
716
Bipolar Disorder01:30

Bipolar Disorder

Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
1.2K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
343
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
304
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
586
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
646